Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEAL-1: HIV Eradication by Combining Agents to Reverse Latency In Vivo
2017-002837-48Phase 4Completed
- Sponsor
- Erasmus MC
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of pyrimethamine and valproic acid in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in HIV reservoir size (TILDA). Started Jul 2017; status: completed.
02
Drugs
pyrimethaminevalproic acid
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2017-002837-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002837-48.